Emergent Biosolutions
LEI 549300YW6TUOX8BE5103
最も包括的なデータベースを探索
1 000 000
債券
80 234
株
167 970
ETF&投資信託
70 000
インデックス
最も効率的な方法でポートフォリオを追跡
- 債券検索
- ウォッチリスト
- Excelアドイン
取引スケジュール 発行体マップ
クオート
- «
- 1
- ...
- {{ quotes.page - 2 }}
- {{ quotes.page - 1 }}
- {{ quotes.page }}
- {{ quotes.page + 1 }}
- {{ quotes.page + 2 }}
- ...
- {{ quotesLastPage }}
- »
プロフィール
|
Emergent BioSolutions Inc. is a biopharmaceutical company focused on protecting and enhancing life by developing and manufacturing vaccines and antibody therapeutics that are supplied to healthcare providers and purchasers for use in preventing and treating disease. The Company operates in two divisions: BioDefense Division and BioSciences Division. It derived substantially all of its product revenues from sales of BioThrax to the United States government, specifically and the United States Department of Health and Human Services (HHS), as well as the United States Department of Defense (DoD).
|
基本情報
-
組織名Emergent Biosolutions Inc
-
組織ステータスOperating organization
-
住所400 Professional Drive Suite 400 Gaithersburg, USA, 20879
-
サイト
IFRS/US GAAP報告書
| 2025 | |
| 2024 | |
| 2023 | |
| 2022 | |
| 2021 | |
| 2020 | |
| 2019 | |
| 2018 | |
| 2017 | |
| 2016 | |
| 2015 | |
| 2014 | |